Telomerase gene therapy: Bolstering our fight against alzheimer’s disease
Nov 13 , 2018

Telomerase gene therapy: Bolstering our fight against alzheimer’s disease

Telomeres are the sentinels of our genes. These genetic sequences sit at the end of our chromosomes guarding them from the ravages of age and time. But each time our cells divide (they don’t replicate forever) – these telomere “guards” get a bit shorter, a bit weaker – a process that has been associated with ageing, cancer, other diseases and death. While shorter telomeres are not the only reason we age and die, they are a contributing factor.

Research also shows that in Alzheimer’s patients, telomere shortening happens at an accelerated rate. An important agent that protects our cells from telomere shortening is an enzyme called telomerase. It is a chemical that adds length bases to the ends of our telomeres, keeping them from being too worn out. There is also evidence that indicates that telomerase plays an active role in our central nervous system from pathological pathways that can lead to neurodegenerative diseases. Integrated Health Systems (IHS) is testing telomerase gene therapy in its objective to battle this difficult disease. Learn more about BioViva and IHS’s treatment for Alzheimer’s by going here:

Adam Alonzi

Adam Alonzi is a writer, biotechnologist, documentary maker, futurist, inventor, programmer, and author two novels. He is an analyst for the Millennium Project, and Head of Social Media and Content Creation for BioViva Sciences. Listen to his podcasts here. Read his blog here.